Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary
March 20, 2025
Earnings Call Speaker Segments
Ed Berg
executiveHello, everybody, and thank you for being with us on this afternoon's call. Joining us from Vaxart are Steven Lo, our Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr. James Cummings, our Chief Medical Officer; and Phillip Lee, Chief Financial Officer. Before we begin, please be aware that during this conference call, Vaxart may issue forward-looking statements. Such statements cover the company's financial results, financial guidance, future business strategies and operations, and product development and regulatory progress, including statements concerning its ongoing or planned clinical trials. What we actually achieve may end up looking quite different from what these forward-looking statements suggest, and that gap could be significant. A range of substantial factors could cause it — among them the unpredictability that naturally comes with developing drugs clinically and navigating the regulatory system, plus the additional risks laid out under the Risk Factors heading in the latest Form 10-K annual report Vaxart has filed, as well as in its other periodic SEC filings. Following today's call, Vaxart has no duty to revise any of these forward-looking statements. At this point I'll hand things over to Steven Lo. Steve?
Steve Lo
executiveThanks, Ed, and I appreciate everyone being with us this afternoon. During today's call, I'll walk through how our business is progressing. After that, James and Sean will provide updates on our clinical and preclinical programs, and then Phil will go over our financial results before we take your questions. Here at Vaxart, we aim to revolutionize global public health through the creation of next-generation oral pill vaccines that bolster pandemic preparedness and give Americans as well as people worldwide a groundbreaking new way to get vaccinated. Vaxart has assembled a substantial collection of data from numerous clinical studies, and we think our approach could deliver meaningful safety and immune response advantages over approved injectables; we have several programs in clinical development that rest on the strength of our oral vaccine platform. This platform is what has produced encouraging data so far, captured in a pill format capable of tackling many weaknesses of injectable vaccines. Our candidates have shown broad immune and cross-reactivity responses, decreased viral transmission and shedding, extended duration of protection and immune responses and notably, a favorable safety and tolerability profile, spanning 19 clinical trials, targeting 7 different viruses and evaluating over 800 participants, our vaccine candidates have demonstrated positive safety data. Beginning with our COVID-19 program, as we've mentioned before, we were granted an award of roughly $460 million to run a study of approximately 10,000 participants in a head-to-head comparison against an available mRNA comparator. In November 2024, we finished enrolling the initial sentinel cohort of the study, which consisted of 400 participants, with 200 getting Vaxart's XBB strain COVID-19 vaccine candidate and 200 getting an approved XBB mRNA vaccine comparator; in January, an independent Data Safety Monitoring Board advised that the study continue without changes following its initial safety review of the 30-day data. On February 21, we got a stop work order tied to this BARDA-funded project Next-Gen award from the U.S. Department of Health and Human Services or HHS; no reason was given to us for the stop work order. It brought to a halt all activities involving the planned 10,000 participant portion of the study and remains active for as long as 90 days. During this 90-day window, the stop work order will either be lifted, prolonged or work on this project will be ended. To be clear, this doesn't affect efforts tied to the 400-person sentinel cohort of the study and activities to monitor and further evaluate this cohort are ongoing. Vaxart shares HHS and BARDA's vision of boosting efficiencies while safeguarding Americans from known and emerging disease threats, as shown by the progress we made with our oral vaccine pill candidates. We understand how much oversight, transparency, and fiscal responsibility matter when it comes to biomedical research funded by the government, and we're dedicated to collaborating with Secretary Kennedy, HHS, BARDA, and others in President Trump's administration as they weigh their priorities and the data behind the 10,000 participant portion of the Phase IIb study, and decide if and how that study should proceed. With our BARDA contacts, we keep up regular communication, mainly regarding follow-up work for the Sentinel Group. Right now, there's nothing new we can share about the 10,000 participant portion of the trial; once we have more information, we'll give an update. The company is still dealing with the fallout from the stop work order, which includes making the expense adjustments required to lengthen our cash runway. Now onto our norovirus program. We're achieving significant progress on our key milestones, and we're glad to have started a Phase I trial earlier this month, testing our second-generation oral norovirus vaccine constructs head-to-head versus our first-generation constructs; in our view, this was a sensible and responsible route consistent with FDA recommendations, following the constructive discussions we had previously with the agency. Should the Phase I trial succeed, the next step, contingent on a partnership or other funding, would be a Phase II safety and immunogenicity study that might potentially start as early as the second half of 2025; an end of Phase II meeting with the FDA would come after this Phase II trial. A Phase III trial might then start as early as 2026, contingent on a successful end of Phase II meeting and funding. As of now, no vaccines against norovirus have been approved. This winter proved especially difficult, with many reports of norovirus spreading throughout the United States and across the world. Norovirus isn't merely a cruise-ship virus; it's extremely contagious and stands as the top cause of acute gastroenteritis symptoms like vomiting and diarrhea; this $10 billion annual U.S. economic burden can impact up to roughly 20 million Americans, which further highlights the unmet need we're committed to addressing. Lastly, we're still carefully examining our preclinical programs before deciding whether additional investment is necessary to move other indications forward. Our Avian Influenza and HPV vaccine programs are two such indications under evaluation. Sean will soon give an update on these programs. I'll now hand the call over to James for a deeper review of recent progress in our norovirus program.
James Cummings
executiveThanks, Steve. Our promising norovirus vaccine candidate is still in clinical development, and Vaxart keeps achieving significant progress with it. We began a Phase I trial earlier this month, testing our second-generation oral norovirus vaccine constructs side by side with the first-generation ones. Sean will go into more detail about the new constructs soon. This study is an exciting one, though—it will assess safety and immune parameters linked to protection in the completed norovirus challenge study. Let me remind everyone why we chose this path. Through gathering data from the first-generation constructs, we were able to measure efficacy against a strong controlled human infection model and pinpoint key immune markers that correspond with norovirus protection. Crucially, our oral norovirus vaccine candidate has been shown to trigger mucosal and systemic immune responses, and it has produced protection tied to a functional antibody response to norovirus in the serum as well as norovirus-specific fecal IgA antibodies. In our Phase II challenge study last year, we saw encouraging data regarding the potential for our oral pill vaccine to lower rates of norovirus infection, illness and viral shedding. Also, in our Phase I clinical trial centered on lactating mothers, we showed positive data indicating our vaccine candidates might help protect infants via passive antibody transfer. Beyond the strong immunogenicity and promising efficacy profile, our norovirus program has shown a benign safety and tolerability profile, in line with the safety of our platform in earlier studies. As shown previously in our challenge study, adverse events did not differ significantly between our vaccine candidate and placebo. We now have promising preclinical data for our norovirus GI.1 and GII.4 constructs, which we think may be more potent than the first-generation constructs currently being evaluated in clinical trials. We are testing that hypothesis so we can proceed with the right dose of the right construct. The combined preclinical and clinical data, together with the constructive feedback on the COVID protection data we submitted, makes us optimistic that we will have the safest and most effective norovirus vaccine candidate in clinical development. We look forward to reviewing the top line noro-data expected as early as mid 2025. I'll now turn the call over to Dr. Sean Tucker, our Founder and Chief Science Officer, for a brief discussion of our norovirus second-generation constructs, recent publications and preclinical programs. Sean?
Sean Tucker
executiveThanks, James. To begin, I want to emphasize the work on our next-generation vaccine constructs and go into more depth about what came out of our latest papers in Science Translational Medicine. Using machine learning, we developed novel second-generation norovirus GI.1 and GII.4 constructs. Our preclinical data indicate that these new constructs pack more punch than the first-generation norovirus constructs that we had already tested in human trials. These second-generation constructs are built to produce the antigenic protein at elevated levels within the intestinal space, which is where our vaccine is delivered once it is released from the tablet. We managed to boost expression through minor modifications to the DNA sequence; in preclinical models, that greater expression has produced markedly stronger immune responses than what we saw with our first-generation constructs. On top of that, these new constructs benefit from recent backbone modifications intended to enhance RNA stability. We expect these gains will carry over into better results in people, whether by triggering stronger immune responses, by achieving a comparable response with a smaller dose — what's known as dose sparing — or by doing both. As James noted, we're eager to demonstrate how much more potent our new constructs are relative to our first-generation ones in a Phase I study that got underway earlier this month; on March 5, Science Translational Medicine ran two papers on our norovirus research that highlighted how efficiently our platform generates mucosal antibody responses. Let me begin with our Phase Ib trial, which assessed the safety and immunogenicity of our first-generation oral norovirus vaccine candidate across two groups of healthy older adults, ages 55 to 65 and 66 to 80; we shared the data via a press release, but I'd like to call attention to several key findings from that study. To start, the vaccine candidate produced strong and lasting systemic antibody responses, induced VP1-specific mucosal homing antibody-secreting B-cells, and triggered mucosal homing T-cells. These findings back the immunogenicity of the vaccine candidate in a patient population that frequently experiences age-related declines in immune responses to injected vaccines. Next, giving the vaccine orally sparked robust and durable IgA responses in the saliva and the nasal cavity, which could carry significant implications for how our vaccine platform is used for norovirus and for other indications too. And finally, the vaccine proved safe and well tolerated among older adults — every solicited event was mild to moderate, with no grade-3 events tied to the vaccine. Given these results, our oral pill norovirus vaccine program may hold a unique position to shield elderly individuals from poor norovirus infection outcomes and to safely deliver the advantages of a mucosal vaccine to patients facing greater risk of adverse norovirus outcomes. The second paper in Science Translational Medicine centered on pinpointing broadly neutralizing antibodies that target human norovirus and on establishing the biochemical and structural basis of broad humoral protective immunity. The bulk of this effort was carried out by two academic teams, one at UT Austin and another at the University of North Carolina. For in-depth studies, we chose two donors. Each of these participants got one dose of our oral candidate vaccine, GII.4, and we picked them according to how their immune systems responded to norovirus after vaccination. For participant A, vaccination greatly increased ligand binding blockade serum titers — all tested GII.4 variants circulating showed a 3.5 to 68-fold rise on day 29, relative to revaccination serum obtained on day -1. Participant B's serum displayed remarkable cross-genotype blocking breadth, spanning 7 GII and 2 GI genotypes on day -1 prior to vaccination, and rose modestly, 2.0 to 3.6-fold, at day-29 following vaccination. The data indicate that immune imprinting mostly shapes how adults respond to mucosal norovirus vaccination, producing a highly cross-reactive response instead of merely a strain specific one resulting from earlier norovirus exposure. The oral vaccine probably strengthens those cross-strain responses. In fact, multiple monoclonal antibodies were isolated from orally vaccinated subjects, and a large number of them were found to bind conserved epitopes of norovirus, which produced that cross reactivity; we consider these published data extremely compelling from both the efficacy and safety perspectives, and they back the continued advancement of our promising norovirus vaccine candidate. I want to use this moment to thank our amazing R&D team and our collaborators for their support in running these studies and enabling these publications. As Steve said before, we are reviewing our preclinical programs as we determine the next steps for bringing future candidates into the clinic. Regarding Avian influenza, we published data showing protection of a preclinical model following oral immunization, and we recently developed a new vaccine candidate covering the latest clade 2.3.4.4b strain. We are currently running several preclinical studies to assess the new construct and getting ready to manufacture for clinical use. For our HPV vaccine, we have further preclinical studies planned to better characterize the immune stimulating antitumor activity of this candidate. Data published previously indicated our mucosal vaccine platform could be a possible noninvasive way to prevent progression to cervical cancer. Once our preclinical studies are finished, we will publish the results. I will now turn the call over to Phil Lee, our CFO, for a brief discussion of our financials. Phil?
Phil Eric Lee
executiveThanks, Sean. Today's press release contains a summary of the details of our financial results for the full year 2024. For 2024, revenue came in at $28.7 million, versus $7.4 million during 2023. The revenue in 2024 came mainly from government contracts tied to BARDA plus noncash royalty revenue generated by Inavir sales in Japan. The revenue in 2023 came mainly from revenue recognized for work performed under the grant Vaxart received from the Bill & Melinda Gates Foundation plus noncash royalty revenue generated by Inavir sales in Japan. Vaxart finished 2024 with cash, cash equivalents and investments totaling $51.7 million. During the first quarter of 2025, the company put measures in place to cut expenses, among them a reduction in its workforce, after the BARDA stop work order. According to our current plan, Vaxart expects cash runway into the fourth quarter of 2025. Vaxart keeps exploring various strategies for extending its cash runway via strategic partnerships, non-dilutive funding and other cost reduction initiatives. I will now hand the call back to Steve for closing remarks.
Steve Lo
executiveThanks, Phil. Everyone on the Vaxart team is committed to changing how we think about public health worldwide. Moving vaccine development forward takes a great deal of time and money, and that's the work we're doing so that our vaccines end up not only extremely effective but also safe. A key part of what we see as the path to success is our distinctive approach built around mucosal immunity, and we feel that our favorable safety and tolerability data strengthens the trust we place in our science. Being pioneers in oral vaccines, we're proud to deliver truly novel advances to this area. What drives our team's enthusiasm daily is the wish to protect individuals from infectious diseases and help them enjoy longer, healthier lives. In 2025 and afterward, we're eager to update you on how we're doing. Prior to taking questions on this call, we ask that those listening refrain from asking anything about the HHS stop work order directive. As mentioned before, we have nothing further we can share right now, which means we're unable to say anything more on the subject; we thank you for understanding. Thank you all for being here today. At this point, we'll begin taking your questions.
Cheng Li
analystCongratulations on the advancement and the paper in Science Translational Medicine. We have a few questions about the new Phase I trial for norovirus. Could you discuss if the new or second-generation product is bivalent versus a monovalent vaccine? Also, for that Phase I study, do you intend to include both young adults and older adults?
Steve Lo
executiveHello, Cheng, thank you for asking. I'll have James and Sean respond to that. James, would you like to start?
James Cummings
executiveAbsolutely. Thank you, Steve. Regarding the Phase I trial, Cheng, participants between the ages of 18 and 49 are being recruited into the study group. As for the second-generation product, our focus is on a GI.1 and a GII.4, and I'll pass it over to Sean to provide a bit more clarity on what that second-generation product could look like. Sean?
Sean Tucker
executiveAbsolutely. We did make a few tweaks to the DNA backbone and to that antigen sequence, and what we discovered is that those tweaks resulted in — they were really small adjustments meant to boost expression within intestinal epithelial cells. After we introduced those constructs into preclinical models, we observed that the animals generated significantly stronger immune responses against the chosen antigen compared with our first-generation version. Naturally, we're quite optimistic, and we've advanced this into the clinic.
Cheng Li
analystUnderstood. And perhaps one brief additional question. Could you possibly give us some detail regarding how extensive the top line data will be that we ought to anticipate around the middle of the year?
Steve Lo
executiveI'll handle that one, Sean. So regarding the top line data we would be anticipating, it covers safety along with preliminary safety and immunogenicity.
Madison El-Saadi
analystMadison here, filling in for Mayank. I'm curious about the second-generation version. The animal data you mentioned showed a stronger immune response. I'm just wondering how that might translate into top line efficacy compared with what we've observed from the earlier first-gen? And I also want to know, will the data from the first-gen still play a role in FDA discussions?
Steve Lo
executiveYes. Thanks for the question. I'll — go ahead. I was about to let James and Sean handle that. From where we sit, right, even with the first construct, the first version, our results were pretty good. But please go ahead, James.
James Cummings
executiveActually, I'll have Sean go first, and I'll back clean up. Sean?
Sean Tucker
executiveRight, so with the new constructs, we're aware they generate stronger immune responses in animals. And again, what we anticipate is that even a modest shift in humans—thanks to that exponential amplification of the signal—will translate into a substantial difference when it comes to protective efficacy. Once more, this comes by way of mathematical modeling; we believe we understand which antibodies are required in the intestinal space, and also when we measure them in serum, and we believe that even slight increases would be remarkably better from an efficacy standpoint. I'll let James take the regulatory question.
James Cummings
executiveAlso, when you look at it from the regulators' perspective, what matters most for us is identifying the proper construct and the proper dose going ahead. It's my belief that this is going to be included in the broader conversation, since our aim is to select the optimal vaccine to deliver to individuals in order to safeguard them.
Liang Cheng
analystLiang Cheng here, filling in for Roger Song. My first question concerns the norovirus program. Congratulations on the early progress in the Phase I study. As I understand it, this will be a head-to-head comparison against your first-gen construct. For the top line readout, which immunogenicity measurement should we be watching? And how do you expect that to translate into protection efficacy?
Sean Tucker
executiveYes. What I'd say is that there are two things we'll initially assess in that trial. One is the serum response we refer to as NBAA, meaning norovirus blocking antibody assay titers; we know that in our clinical study, or the challenge study, that correlated quite well with protection. The other thing we'll assess is fecal IgA; and once again, that was also among the top line data that matters most when it comes to billing efficacy in that challenge model.
Liang Cheng
analystThank you, John. Perhaps one more question, this time about the second-generation construct. You said it has greater potency. How should we view that in terms of the dosage intended for a clinical trial, relative to the first-generation?
Steve Lo
executiveAbsolutely. I'll handle that one, Sean. We are currently signing up 60 patients overall in the Phase I study, split into 3 cohorts of 20 each. When we examine the new construct, it would be regarded as low dose and high dose. Meanwhile, the traditional, or original, construct would be regarded as the high dose, with attention to both GI.1 and GII.4. Our enrollment approach factors in the leading practices for safety dose and for clinical development. And it's — I'm glad to report it's moving along well.
Liang Cheng
analystPerhaps one last thing about the COVID-19 program. I gather the DSMB has reviewed the data and advised moving forward with no modifications; so has the FDA actually looked at the data from the sentinel cohort?
James Cummings
executiveYeah, James here. We did send the data to the FDA. It went to the DSMB at the same time.
Ed Berg
executiveThanks — we've received quite a few questions from our shareholders. Starting with the first one, and this is obviously directed at Steve: with the regulatory and political landscape being so difficult and changing so quickly, are you running the company in a different way?
Steve Lo
executiveAppreciate that. Thanks for asking. Since we're not a big organization, our approach has always been extremely efficient. Being quick on our feet and able to adjust is something we take great pride in, and that won't change. As everyone listening is aware, vaccine science stands as a tremendous accomplishment of contemporary medicine. That makes them among the strongest instruments we have for fighting infectious illnesses, protecting public health, and so on. It's common knowledge that immunization has dramatically cut down sickness and mortality across the globe. Given our oral vaccine platform, we at Vaxart still see ourselves as an innovator in this space. To this point, it has shown a favorable safety profile comparable to placebo; and we believe that kind of distinguishing feature might help with vaccine uptake, giving both consumers and doctors a wider set of choices. We're definitely grateful for the ongoing conversation we have with FDA, BARDA and HHS. Throughout 2025, our intention has consistently been to move forward with more than one vaccine program, and we're pleased to say that's exactly what we're continuing to do.
Ed Berg
executiveAppreciate it. I've got a few things to ask regarding the COVID-19 program. To start, regarding the DSMB: was there any particular feedback they gave us? And after that, James, perhaps you could also walk through our thinking on the FDA submission, in case anyone isn't clear on it. But for you, James, covering both what's happened when it comes to monitoring and how the scientific bodies have overseen the program?
James Cummings
executiveAppreciate that, Ed. So as we said earlier, the DSMB looked at 30-day safety data covering 400 participants in the sentinel cohort of the COVID-19 Phase IIb study. After going through those results, their recommendation came through quite clearly: the trial should keep going with no changes, according to how they evaluated things. And in our view, that recommendation really highlights the strong safety profile of both our vaccine candidate and our platform — once again, quite comparable to placebo. On the FDA submission side, that data went to the FDA at the same time, and they have gone through it; therefore there is no — no hold on that as far as pushing things ahead. From where we sit, it's — we're on track to carry the program onward.
Ed Berg
executiveAppreciate that, James. Now for the following question: in what ways does the stop work order affect manufacturing? Had the product for the trial already been made? If that's the case, how long is its shelf life? Should the stop-work order continue for a full 90 days or beyond, is there any way to salvage it? So those are questions regarding manufacturing along with how the product we've made gets used, and on that note, I'll turn it over to Ray Stapleton, our Chief Technical Officer, to respond; he's with us here.
Executive
executiveAppreciate that, Ed. It works in our favor that our own GMP production sites are operated by us, and every one of them sits within the U.S. That setup let us shift direction fast to back this trial. You could see it in action: first we made product aimed at the X-BB strain of COVID, and after that we made product aimed at the KP.2 strain of COVID. Under our continuing production strategy, we check product stability on a regular basis, and looking at the stability data we've gathered across our platform so far, we expect shelf life to reach 2 years. Once the stop-work order became clear to us, we stay confident in our ability to adapt to it.
Ed Berg
executiveThe following question concerns our norovirus program, and it has to do with how we view the market opportunity, since a competitor is already at Phase III, and I'll have Steve respond to that.
Steve Lo
executiveAbsolutely, and I appreciate you raising that. Whenever a major corporation possessing substantial means concludes that a serious unmet need exists, that gives us encouragement, since our own view aligns with theirs. So indeed, norovirus represents a sizable market opportunity, one that carries a $10 billion impact on the U.S. And we definitely think consumers along with physicians will value having choices when it comes to future vaccines. Naturally, in our view an oral alternative will prove competitive within the marketplace. And, as discussed previously, we're thrilled to be on track for top line data from our Phase I as early as midyear this year.
Ed Berg
executiveThanks. I’ve got some questions for Sean about our other programs. To start, when should we expect news on the preclinical work you’re doing in influenza and HPV? Then I have a separate follow-up. Can Vaxart find a way to move faster on the bird flu vaccine?
Sean Tucker
executiveOkay, thank you. At this time, the company is carrying out a number of preclinical studies so we can assess our second-generation construct, and we're also getting ready to produce that construct for use in the clinic. Naturally, once those preclinical studies wrap up, we'll release the findings.
Ed Berg
executiveAppreciate it. Now, there's a finance-related question here. Which kinds of partnership funding or non-dilutive funding are you looking at? I'll turn that over to Phil for the response.
Phil Eric Lee
executiveAppreciate that, Ed. So we have — we truly keep talking with people and genuinely bring certain parties up to speed as things move forward with our platform and programs. On top of that, we take part in conferences on both the financial side and the scientific side, which is where we meet new third parties. Broadly speaking, we feel quite encouraged that quite a few of these parties keep expressing interest in our vaccine candidates and, really, in what the oral pill vaccine platform could offer. While there's nothing more we can share right now, we will definitely put out announcements once the moment is right and there's something to tell.
Ed Berg
executiveAppreciate that, Phil. That wraps up all the inquiries we received. So with that, I'll hand things back to the operator to bring our session to a close.
Operator
operatorThanks. And everyone, that brings today's call to an end, so you're free to hang up now. We appreciate you joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.